Moving away from recommendations dating back to 2009, the U.S. Preventive Services Task Force now states that women should start biennial screening for breast cancer at age 40—instead of 50—a change that experts say is based on new, inclusive science.
The U.S. Preventive Services Task Force’s latest draft recommendation on breast cancer screening is based in part on data on racial disparities in breast cancer mortality.
This week, the U.S. Preventive Services Task Force published a new draft guideline on breast cancer screening.1 The task force is considered the most rigorous and orthodox authority on the interpretation and application of the medical literature. The panel is widely respected for its expertise in epidemiology, screening, clinical trials interpretation, and structured reviews of... […]
The latest draft guideline by the U.S. Preventive Services Task Force is part of a 50-year controversy over the appropriateness of screening women between the ages of 40 and 49.
Researchers at Baylor College of Medicine and collaborating institutions have identified a strategy cancerous tumors use to remotely disrupt the development of an immune response that could stop their growth.
Susan G. Komen appointed nine medical and research experts to serve as advisors to the organization.Â
A team of scientists led by Scott Abrams at Roswell Park Comprehensive Cancer Center uncovered a pathway associated with metastases to the lung, a common site for cancer spread. The work, just published in JCI Insight, has potentially significant implications that may point to novel cancer therapies.
While trying to understand what initiates breast cells to become cancerous, researchers at the Vera Bradley Foundation Center for Breast Cancer Research at Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a new target for breast cancer treatment.
A large retrospective study conducted by physician researchers from Roswell Park Comprehensive Cancer Center shows benefits of chemotherapy for many patients with early-stage breast cancer with rare variant histology, or tumor anatomy. These findings were presented by first author Arya Mariam Roy during the American Association for Cancer Research annual meeting.
To provide a roadmap for accelerating progress against breast cancer over the next 10 years, an expert panel was convened at the 2022 San Antonio Breast Cancer Symposium to identify the biggest obstacles hindering our ability to cure breast cancer and to propose transformative solutions to address these obstacles.
